Eating Disorders & GLP-1 RAs

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes. LP-1 RAs are now being used as an approved or off-label treatment for weight loss.

here is limited research available to help researchers, clinicians, and patients/consumers to understand the relationships between GLP-1 RAs and eating disorders (9). However, it is thought that GLP-1 RAs may negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information for clinicians, researchers, and patients/consumers to understand more about the link between GLP-1 RAs and eating disorders, including risks, physical impacts, psychological impacts, and practice recommendations.